Kymera Therapeutics Cash Flow Statement (2019-2026) | KYMR

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income (Quarter)
-270.29M-34.03M-168.49M-85.35M-94.40M-38.69M-112.45M-166.93M-185.39M-68.93M-189.04M-107.96M-221.31M-80.77M-196.41M-218.80M-342.58M-97.90M-494.75M-729.42M
Depreciation and Depletion (Quarter)
700.002.40M0.70M0.70M0.80M0.80M0.90M0.90M0.90M0.90M1.50M1.90M2.00M2.00M1.60M1.70M2.10M2.90M1.60M1.60M
Share-based Compensation (Quarter)
7.40M-15.99M7.87M9.62M9.08M9.38M11.18M11.65M10.90M11.97M14.34M14.90M-41.21M14.23M15.41M73.50M-45.45M16.01M18.94M
Asset Writedowns and Impairment (Quarter)
4.92M3.85M0.04M
Cash from Operations (Quarter)
-37.26M-38.35M-40.30M-38.98M-34.27M-39.54M-43.97M-35.26M-31.65M8.04M-39.59M-42.94M-50.19M-61.78M-79.15M-59.88M-27.11M-66.75M-88.84M-54.06M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter)
0.67M0.69M0.69M0.70M0.77M0.82M0.88M0.90M0.90M0.89M1.46M1.94M1.99M1.99M2.05M2.08M2.15M2.03M2.02M2.03M
Change in Working Capital
Change in Account Payables (Quarter)
-2.92M-1.03M-1.44M-0.41M4.17M-2.07M2.22M-2.73M1.02M1.53M0.07M0.03M0.09M-0.51M3.92M-4.13M-0.27M-1.49M8.82M-3.94M
Change in Accured Expenses (Quarter)
4.71M3.80M-2.28M0.56M3.40M2.84M-10.04M3.79M2.64M6.79M-15.39M7.80M2.75M9.02M-11.69M4.75M0.66M13.66M-7.21M13.49M
Other Working Capital Changes (Quarter)
1.65M2.95M0.59M-1.06M0.99M0.48M1.64M7.91M-5.18M14.20M2.64M-0.56M0.97M-1.13M-1.15M-1.26M-1.30M-1.33M3.56M-0.22M
Investing Activities
Capital Expenditures (Quarter)
0.31M0.90M0.48M0.73M1.25M-1.47M4.01M10.77M-14.78M-0.91M7.40M4.69M-0.19M0.94M0.47M0.69M0.18M5.82M0.43M-2.16M
Change in Acquisitions & Divestments (Quarter)
109.29M96.88M106.46M147.25M117.67M97.94M90.43M99.25M97.76M76.08M99.50M124.49M138.07M147.93M132.74M118.97M132.44M103.87M133.86M135.17M
Cash from Investing Activities (Quarter)
-136.86M-68.02M25.86M81.80M-37.48M-49.67M24.58M35.84M60.51M18.95M-330.61M15.64M-157.68M68.57M48.62M60.02M-235.30M-394.40M-142.84M20.05M
Financing Activities
Other financing activities (Quarter)
5.53M-5.09M0.26M0.27M-0.28M2.90M2.16M-1.16M1.86M48.74M-39.12M-8.04M0.28M-0.28M12.79M48.83M0.42M13.38M
Cash from Financing Activities (Quarter)
246.04M2.05M0.18M0.36M150.50M1.95M1.16M1.30M-0.21M1.93M353.76M1.41M250.92M2.77M0.26M245.73M39.51M705.22M18.77M14.42M
Change in Capital Stock
Net Equity Issued and Repurchased (Quarter)
Additional items
Change in Cash (Quarter)
71.92M-104.32M-14.25M43.18M78.75M-87.25M-18.23M1.89M28.66M28.93M-16.44M-25.88M43.05M9.55M-30.28M245.86M-222.90M244.07M-212.91M-19.60M
Free Cash Flow (Quarter)
-37.57M-39.25M-40.78M-39.72M-35.52M-38.07M-47.98M-46.02M-16.87M8.95M-46.99M-47.62M-50.00M-62.72M-79.62M-60.58M-27.29M-72.57M-89.27M-51.90M
Net Cash Flow (Quarter)
71.92M-104.32M-14.25M43.18M78.75M-87.25M-18.23M1.89M28.66M28.93M-16.44M-25.88M43.05M9.55M-30.28M245.86M-222.90M244.07M-212.91M-19.60M